<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683263</url>
  </required_header>
  <id_info>
    <org_study_id>07CRT_VV_323_18-003</org_study_id>
    <nct_id>NCT04683263</nct_id>
  </id_info>
  <brief_title>Immediate and Mid-term Effect of a Natural Topical Product in Patients With Musculoskeletal Pain</brief_title>
  <official_title>Immediate and Mid-term Effect of a Natural Topical Product in Patients With Musculoskeletal Pain: a Randomized, Double-blinded, and Placebo-controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uriach Consumer Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quironsalud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uriach Consumer Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Musculoskeletal pain is a common affection due to ageing, sedentarism and intense exercise&#xD;
      practice causing acute and chronic injuries.&#xD;
&#xD;
      The main objective of this trial is to prove efficacy of a natural topical composition&#xD;
      containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and&#xD;
      menthol in pain management in adults with acute or chronic pain.&#xD;
&#xD;
      This randomized, double-blinded and placebo-controlled trial will include 200 patients with&#xD;
      musculoskeletal pain, 100 in the intervention group receiving the topical formula and 100 in&#xD;
      the placebo group, who will receive a similar formula without active ingredients.&#xD;
&#xD;
      The products will be applied topically twice daily for 14 days in areas with moderate or&#xD;
      severe pain.&#xD;
&#xD;
      The study objectives are immediate and long-term pain alleviation, stiffness perception joint&#xD;
      mobility, and general recovery perception.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Well-being is understood as the absence of limitations or debilitating conditions that make&#xD;
      impossible to enjoy a full and satisfactory life. Among these limitations, a reduced or&#xD;
      impaired motility because of painful and inflammatory processes (acute and chronic), can&#xD;
      greatly disturb a vital and optimistic attitude.&#xD;
&#xD;
      Chronic pain affects between one-third and one-half of the population only in the UK, and&#xD;
      around 20.4% in the US. It is likely to increase with population ageing and tends to be more&#xD;
      common in women. Ageing is translated in an increase in the incidence and span of chronic&#xD;
      illnesses, including osteoarthritis, fibromyalgia, lower back pain, non-arthritis joint pain&#xD;
      or carpal tunnel syndrome, among others. In addition, muscular and joints pain unrelated to&#xD;
      any specific disease also tends to appear with age. Beyond that, current lifestyle frequently&#xD;
      involves stressful jobs, eventful agendas and non-stop activity either in professional or&#xD;
      leisure time. These facts extend the prevalence of chronic pain to younger segments of the&#xD;
      population and to people not affected by previous disease.&#xD;
&#xD;
      Sedentary lifestyle and computer-based jobs represent a common cause of muscular contractures&#xD;
      and pain, especially in the back and neck areas. Another important contributor to chronic&#xD;
      pain is perceived stress and anxiety response systems. As an emergent antagonist phenomenon,&#xD;
      increasing awareness of a healthy lifestyle has entailed a rise in the popularity of physical&#xD;
      exercise in the last decades. As an example, the number of running events finishers in the&#xD;
      U.S. stabilized in 2014 at almost 20 million people, with figures having been on the rise for&#xD;
      the previous 25 years. The popularization of exercise programs such as CrossFit illustrate&#xD;
      that the trend is directed not only towards a rise in practice, but also in intensity. Thus,&#xD;
      the increase in the practice of high-intensity physical activity and the alternation between&#xD;
      sedentary and exercise periods involve an increase in inflammatory and acute painful&#xD;
      episodes, being tendinitis and joint lesions the major problem, followed by sprains or&#xD;
      bruises.&#xD;
&#xD;
      The pharmacological management of these conditions involves nonsteroidal anti-inflammatory&#xD;
      drugs (NSAIDs), local corticosteroids, acetaminophen, chondroitin sulfate or even opioids.&#xD;
      These are effective drugs but with serious side effects in some cases, especially in the&#xD;
      long-term utilization. Severe drawbacks related to the prolonged utilization of these drugs&#xD;
      include drug ineffectiveness, toxicity of certain agents, hypersensitivity, gastrointestinal&#xD;
      hemorrhage, nauseas and even fatal outcomes including death and suicide. Importantly,&#xD;
      increased abuse of painkillers has been reported in several countries, exceeding tobacco&#xD;
      consumption and being considered a public health problem. Furthermore, the use of painkillers&#xD;
      should be avoided in sensitive population groups including children and pregnant women, who&#xD;
      are equally exposed to sustained or acute pain episodes.&#xD;
&#xD;
      Alternative solutions of greater safety but equivalent rapid relief and recovery&#xD;
      effectiveness are a necessity. In this sense, the most useful approach are natural products,&#xD;
      without tolerability concerns, compatible with other interventions and providing a rapid&#xD;
      effect. These generalize access to effective treatment to both patients and physiotherapy&#xD;
      professionals. Considering the well-established beneficial effects of physiotherapy in&#xD;
      handling chronic pain, professionals need effective and safe solutions that they can use&#xD;
      without concerns of side effects or pharmacological interactions, since they may not have&#xD;
      access to the full medical record of the patients. In turn, the ability of handling&#xD;
      self-treatment without concern increases the quality of life in patients suffering from&#xD;
      pain-involving conditions.&#xD;
&#xD;
      This study evaluates the use of a topical cream composed by natural extracts with&#xD;
      complementary and synergistic effects for pain management. Menthol reduces pain and increases&#xD;
      blood flow, warming up the muscle and enhancing absorption of the rest of the extracts.&#xD;
      Arnica montana reduces pain, has anti-inflammatory effects and potentiates tissue repair.&#xD;
      Hypericum perforatum provides anti-inflammatory effect and drives tissue regeneration and&#xD;
      scarring. Calendula officinalis reduces swelling and distension, boosts healing of mild&#xD;
      injuries and prevents infection. Finally, Melaleuca alternifolia complements the&#xD;
      anti-inflammatory effect and acts as a natural preservative due to its potent antimicrobial&#xD;
      effect.&#xD;
&#xD;
      The synergistic combination of these natural ingredients may provide a convenient solution&#xD;
      for the management acute or chronic pain. The aim of this study is to assess the benefits of&#xD;
      the topical formulation in reducing musculoskeletal pain, both as an immediate relief of pain&#xD;
      and as a solution for injury recovery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, double-blinded and placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Patients were randomly assigned, using the Excel (Microsoft) RAND function, into 2 groups: treatment group and placebo group, a topical cream with similar characteristics and aspect, without active ingredients. Allocation was concealed from the recruiter and participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Average variation in pain at rest</measure>
    <time_frame>14 days (0, 7 and 14 days)</time_frame>
    <description>pain reduction after intervention measured as per a Visual Analog Scale (1 - 10, higher values indicating more pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average variation in pain in motion</measure>
    <time_frame>14 days (0, 7 and 14 days)</time_frame>
    <description>pain reduction after intervention measured as per a Visual Analog Scale (1 - 10, higher values indicating more pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average variation in pain at rest</measure>
    <time_frame>2 hours (0, 30 minutes, 1 hour, 2 hours)</time_frame>
    <description>pain reduction after intervention measured as per a Faces Scale (1 - 10, higher values indicating more pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average variation in pain in motion</measure>
    <time_frame>2 hours (0, 30 minutes, 1 hour, 2 hours)</time_frame>
    <description>pain reduction after intervention measured as per a Faces Scale (1 - 10, higher values indicating more pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average variation in stiffness at rest</measure>
    <time_frame>2 hours (0, 30 minutes, 1 hour, 2 hours)</time_frame>
    <description>stifness reduction after intervention measured as per a Stifness scale - (0) no stiffness, (1) slight stiffness, (2) moderate stiffness and (3) severe stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average variation in stiffness in motion</measure>
    <time_frame>2 hours (0, 30 minutes, 1 hour, 2 hours)</time_frame>
    <description>stifness reduction after intervention measured as per a Stifness scale - (0) no stiffness, (1) slight stiffness, (2) moderate stiffness and (3) severe stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average variation in stiffness at rest</measure>
    <time_frame>14 days (0, 7 and 14 days)</time_frame>
    <description>stifness reduction after intervention measured as per a Stifness scale -- (0) no stiffness, (1) slight stiffness, (2) moderate stiffness and (3) severe stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average variation in stiffness in motion</measure>
    <time_frame>14 days (0, 7 and 14 days)</time_frame>
    <description>stifness reduction after intervention measured as per a Stifness scale - (0) no stiffness, (1) slight stiffness, (2) moderate stiffness and (3) severe stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery perception</measure>
    <time_frame>14 days (0, 7 and 14 days)</time_frame>
    <description>Subjective perception of recovery as per a Likert scale ((1) meant fully recovered, (2) much better, (3) better, (4) same as before and (5) worse than before.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint mobility</measure>
    <time_frame>14 days (0, 7 and 14 days)</time_frame>
    <description>Joint mobility evaluation as per passive joint balance ((1) free mobility, (2) partial limitation, (3) moderate limitation and (4) severe limitation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Musculoskeletal Pain</condition>
  <condition>Chronic Pain</condition>
  <condition>Joint Pain</condition>
  <condition>Stiffness of Unspecified Joint, Not Elsewhere Classified</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FisiocremÂ®, a topical cream composed of the natural ingredients Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical cream with similar characteristics and aspect, without active ingredients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>topical cream with same composition as Intervention but without active ingredients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fisiocrem</intervention_name>
    <description>a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute or chronic musculoskeletal pain scoring above 4 in the Visual Analogue Scale&#xD;
             (VAS)&#xD;
&#xD;
          -  diagnostic of either tendinopathy, vertebral algias, sprains or symptomatic&#xD;
             osteoarthritis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnostic in either neuropathic chronic pain, fibromyalgia or neoplasia&#xD;
&#xD;
          -  allergy to any ingredient in the formula&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Ramon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital QuiroSalud Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QuironSalud Hosiptal</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Musculoskeletal pain</keyword>
  <keyword>Chronic pain</keyword>
  <keyword>Joint mobility</keyword>
  <keyword>Massage</keyword>
  <keyword>Rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

